$MDT

Medtronic announces cash dividend for second quarter of fiscal year 2027

Medtronic plc (NYSE: MDT) declared a $0.72 per share cash dividend for Q2 fiscal 2027, payable October 16, 2026. This matches the increased dividend announced in June 2026. The company has raised its annual dividend for 49 consecutive years. Medtronic is a global healthcare technology firm with a portfolio of medical devices and therapies.

Original reporting
Published Aug 20, 2026, 9:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 9:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medtronic announces cash dividend for second quarter of fiscal year 2027 — source image
Decision brief

The 30-second read

$MDTBullishLow
01

Why it matters

The $0.72 dividend represents a modest increase, likely to be priced in quickly, offering limited trading edge.

02

Market read

A routine dividend announcement with modest upside for income‑oriented traders; minimal broader market effect.

03

What to watch

Potential tax considerations for dividend‑capture strategies and upcoming earnings guidance.

Relevance 5/10Novelty 5/10Timing: record date Sep 25 2026

Background

Medtronic is a long‑standing member of the S&P 500 Dividend Aristocrats with 49 consecutive annual dividend increases.

Company-level read

Ticker impact

$MDTBullishMedium confidence
Context

Medtronic announced a $0.72 per share cash dividend for Q2 FY2027, payable Oct 16 2026 to shareholders of record Sep 25 2026.

Expected impact

Potential slight upside in pre‑record‑date trading as dividend‑capture strategies play out.

Evidence & confidence

The announcement is a primary disclosure but represents a routine corporate action with limited material impact.

Market effects

May reinforce the healthcare sector's appeal to dividend investors.

Limited to U.S. and European markets where Medtronic is heavily weighted.

Low; impact confined to income‑focused investors.

Counterpoint

Dividend hikes can signal limited growth opportunities; investors may prefer growth stocks.

Key entities

  • Medtronic plc

    Global medical technology firm announcing its Q2 FY2027 dividend.

Related articles

$DHRMedAI 8/10

Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?

Danaher (DHR) and Medtronic (MDT) report recovery signs. DHR benefits from life sciences demand, with bioprocessing orders growing mid-teens. MDT shows highest annual revenue growth in 10 years, with Q4 revenue at $9.8B and FY26 at $36.4B. MDT's cardiac segment grew 78% globally, driven by cardiac ablation solutions. Both companies face challenges, with MDT's growth concentrated in a few platforms and DHR's revenue delayed into next year.

$MDTMedAI 8/10

Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

$ISRGMed

Johnson & Johnson and Medtronic Enter the Fray, Squeezing Market Share as Intuitive Surgical Faces Its Biggest Challenge in Recent Years

Intuitive Surgical (ISRG) stock fell 30% in 2026 due to weak guidance, competition, and high valuations. Q2 revenue grew 19%, but full-year procedure growth guidance was below expectations. Competitors like Johnson & Johnson and Medtronic are entering the market, raising concerns about ISRG's market share. Analysts note high valuation multiples and slowing growth may pressure the stock further.